Cic edizioni internazionali
Reviews in Oncology

Neo-adjuvant treatment of Her2-positive early breast cancer: standard of care and future directions

Review, 41 - 47
Tag this article
Abstract
Enhanced HTML Full text PDF
Neoadjuvant therapy (NT) is the standard of care for locally advanced (LA) and inflammatory breast cancer (IBC). In Human Epidermal growth Receptor 2 (Her2) overexpressed or amplified breast cancer the addition of the monoclonal antibody Trastuzumab (T) to standard anthracyclines (A) and/or taxanes-based chemotherapy (CT), resulting in improved pathological complete response rate (pCR) compared with CT alone. However, because of T resistance, new targeted drugs with synergistic and/or complementary mechanisms of action, such as Lapatinib and Pertuzumab, were tested alone and in combination with T as neoadjuvant treatment. This review briefly discusses the clinical role of the main anti-Her2 strategies outlining efficacy, safety and tolerability of dual targeting in a neoadjuvant setting.

Vol. 3 (No. 1) 2015 January - December

  1. Pregnancy in breast cancer survivors: safety and feasibility
    Stani S.C., Sini V.
    doi: 10.11138/rio/2015.1.5.105
Last Viewed articles: la lista degli ultimi x visitati.
  1. Neo-adjuvant treatment of Her2-positive early breast cancer: standard of care and future directions
    Russillo M., Giovannelli S., Tanganelli L., Baldini E.
credits